Kolibri (Tramadol Hydrochloride, Paracetamol)

Tramadol provides weak μ‑opioid receptor agonism and blocks the reuptake of norepinephrine and serotonin, enhancing descending pain inhibition. Paracetamol adds analgesic and antipyretic effects, likely by centrally inhibiting cyclooxygenase enzymes, resulting in synergistic pain control.

The dosage of Kolibri is determined by the prescribing clinician based on the patient’s pain severity, medical history, and response to therapy. The prescriber will select the appropriate strength and dosing schedule in accordance with local regulations.

Safety in pregnancy and lactation has not been definitively established. Kolibri should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Kolibri product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with single‑component opioids, Kolibri combines a weak opioid with paracetamol, offering comparable analgesia with potentially lower opioid‑related side effects. It is often preferred over higher‑dose opioids for moderate pain and provides faster onset than paracetamol alone.

Kolibri tablets should be stored at ambient temperature below 25 °C, in the original packaging, protected from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Kolibri is taken orally with a full glass of water. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any specific dietary considerations.

Serious risks include respiratory depression, seizures, serotonin syndrome when combined with serotonergic agents, severe allergic reactions such as anaphylaxis, and rare hepatic injury. Patients should be monitored closely for these events, especially when initiating therapy or adjusting doses.

Kolibri is contraindicated in individuals with known hypersensitivity to tramadol, paracetamol, or any excipients, as well as in patients taking monoamine oxidase inhibitors. Caution is also advised for patients with severe respiratory disorders, uncontrolled epilepsy, or significant hepatic or renal impairment.